ASCO23 Day 3 :Parp Inhibitors & Late Breaking Abstract session

While there were fewer gynecologic cancer sessions on Day 3, Sunday June 4th there were two important sessions regarding the use of PARP inhibitors and trial results for a drug to teat  platinum resistant ovarian cancer drug which may be change practice.

Parp Inhibitor Optimal Selection and Toxicity Management 

Dr Tew - Status updates on Parp use

Dr Friedlander- Real World Experience in Managing PARP Toxicities 

 

 

 Susan Feinberg  (FORCE) - Living on a PARPi 

 

Late Breaking Abstract Session  

Mirvetixumab in Folate Receptor Alpha positive platinum resistant ovarian cancer

I wish I had been able to be in the room when this session took place. I could feel the excitement from the Tweets being posted.  This is the first trial to show overall survival benefit in platinum resistant ovarian cancer! This is practice changing. 

Wow! Amazing to see an #OverallSurvival benefit for Mirvetuximab for patients with platinum resistant #OvarianCancer
🚨 new standard of care alert 🚨 #GynCSM #ASCO23
Congrats to the investigators and patients who made this #research possible! @ASCO pic.twitter.com/ojYBIDKYS0

— Megan Hutchcraft MD (@MeganLeigh127) June 4, 2023

🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant #ovariancancer. Absolutely new standard of care!! 👏 #gyncsm #ASCO23 pic.twitter.com/yweWSh5qES

— Eleonora Teplinsky, MD (@drteplinsky) June 4, 2023

I shared tweets others wrote about the MIRASOL trial (mirvetixumab in FOLR1 positive platinum resistant #ovariancancer ) but... this slide says it all . #ASCO23 #gyncsm pic.twitter.com/Sif0gn76a8

— Dee Sparacio (@womenofteal) June 4, 2023

 Here is a slide of the overall survival  MIRV 16.46 months vs investigator choice of treatment 12.75 months.

 Stop by tomorrow for highlights from my last day of ASCO - Day 4 . 

Dee

Every Day is a Blessing

2021 SGO Virtual Annual Meeting Saturday March 20

Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021. 

The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags

 Surgery:

Scientific Plenary II: Cutting Edge - Advancing Surgical Innovation -If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer
Dr Katelyn Handley- Looking at morphology and molecular difference in OC #SGOMtg #gyncsm #SGOPatAdv pic.twitter.com/LavQt2RBLp

— Dee Sparacio (@womenofteal) March 20, 2021

Higher Surgical Volume is Associated with Better Outcomes for Frail Patients Undergoing Surgery for Ovarian Cancer- M. Nakhla #SGOMtg #gyncsm pic.twitter.com/3ZU7q8KZ0R

— Dee Sparacio (@womenofteal) March 20, 2021

MEDSCAPE shared this article on MIS and interval debulking surgery. https://www.medpagetoday.com/meetingcoverage/sgo/91738

Equity 

Education Forum V: Eradicating Racism and Discrimination in Medicine Thank you Dr Latimore. #SGOMtg #gyncsm
Have you ever taken a test to measure your implicit bias? I have. Results were not what I expected. We can do better. "See people as an individual." pic.twitter.com/bCEYQ1IDiY

— Dee Sparacio (@womenofteal) March 20, 2021

Education Forum V: Eradicating Racism and Discrimination in Medicine #SGOMtg #gyncsm
Dr Marsh
"We have to see it."
"Honesty is more important than fear"
We need to do this now. pic.twitter.com/48BS8u4I2B

— Dee Sparacio (@womenofteal) March 20, 2021

How to address our own biases? We needs to address our own biases while addressing bigger picture in our society! #SGOMtg #sgo2021 @SGO_org @somedocs #MedTwitter #obgyntwitter #gyninfluencer pic.twitter.com/Kk20tx51YD

— Payam Katebi Kashi, MD, PhD (@PayamKashiMD) March 20, 2021

PAOLA-1 Olaparib plus Bev

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
HR repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
E. Pujade-Lauraine#SGOMtg #gyncsm pic.twitter.com/sEUkrDBAzJ

— Dee Sparacio (@womenofteal) March 20, 2021

Tumor infiltrating lymphocytes

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Keynote 158 Cervical Cancer

Updated data from the KEYNOTE-158 study of pembrolizumab in recurrent #cervicalcancer - response rate of 17% in pts with PD-L1 positive tumors. Median time to response was 2 months- fast acting! Med duration of response not reached... #SGOMtg #gyncsm pic.twitter.com/ut0EinNBvy

— Shannon Westin (@ShannonWestin) March 20, 2021

 

Scientific Plenary III: Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study
H. Chung#SGOmtg #gyncsm pic.twitter.com/qdBegPgXfZ

— Dee Sparacio (@womenofteal) March 20, 2021

 ENGOT-OV 16/ NOVA  niraparib

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Dr Matulonis
ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian #SGOmtg #gyncsm pic.twitter.com/wwd9DwuTho

— Dee Sparacio (@womenofteal) March 20, 2021

PARP Inhibitor duration of follow-up

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Bradley
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Longest duration of follow -up of a PARP inhibitor in trials to date. #SGOmtg #gyncsm pic.twitter.com/hFNBwgsZ5K

— Dee Sparacio (@womenofteal) March 20, 2021

Cervical Cancer Radiation study

#SGOmtg
Translational Research 2021:
Genomic profiling of adv cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial #gyncsm
C. Lan
predictive Biomarker research for cervical cancer pic.twitter.com/IuoDprILOi

— Dee Sparacio (@womenofteal) March 20, 2021

Phase III Ran Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) vs Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER)
S. Chopra
Reduction in diarrhea, #sgomtg#gyncsm pic.twitter.com/iGgp0EEcdF

— Dee Sparacio (@womenofteal) March 20, 2021

Shared Decision Making Tool

Niraparib as Maintenance Therapy- Dr Matalunis https://ascopost.com/videos/sgo-2021-virtual-annual-meeting-on-womens-cancer/ursula-matulonis-on-ovarian-cancer-niraparib-as-maintenance-therapy/

Priority Assessment for Women with Recurrent Ovarian Cancer: A Pilot Study presented by @StephanieVBlank Aids shared-decision making! Feasible with 97% completion! Next steps: Ongoing assessments, electronic version, languages #SGOmtg #SGOPatAdv #GYNcsm pic.twitter.com/hF4ntyzCwk

— Annie Ellis (@Stigetta) March 21, 2021

TY patients 4 insights Priorities Assessment Tool! Prior work https://t.co/O8UAvCtEKC https://t.co/COvGQgQJeN revealed needs-Standardized way 2 individualize tx discussions &capture changes tx goals/priorities along care continuum @MelissaFrey2 @StephanieVBlank #SGOmtg #SGOPatAdv pic.twitter.com/QDhiPDc8vs

— Annie Ellis (@Stigetta) March 21, 2021

Stop by tomorrow for my Sunday highlights.  

Dee

Every Day is a Blessing!

#SGOmtg Twitter Highlights - Research Highlights Monday, March 26, 2018

Monday March 26th was another day of important presentations at the SGO Annual meeting. Some results may change treatment protocols going forward.

Here are the tweets I found of most importance.

Cervical Cancer - Minimally invasive surgery *this one may change how early cervical cancer is treated

Do we need to rethink minimally invasive surgery for cervix? #SGOMtg pic.twitter.com/XTLgg5IO0t

— Erin Stevens (@erinstevensmd) March 26, 2018

Dr Raih Hain of @MDAndersonNews presenting surprising results- our patients with early #cervicalcancer have been doing worse since the adoption of min invasive surgery. Time to rethink practice at the #SGOMtg pic.twitter.com/K3afaUynxe

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Ovarian Cancer Debulking Surgery

No residual disease remains a goal of OvCa debulking surgery. Single site optimal improves PFD and OS as compared to multisite optimal or suboptimally debulked OVCA. Manning-Geist et al #SGOMtg pic.twitter.com/KP0P9SeEAK

— Rick Boulay,MD (@journeycancer) March 26, 2018

Excellent talk on #ovariancancer surgery by @AnilSoodMD at the #SGOMtg @SGO_org @MDAndersonNews pic.twitter.com/IiXT5YbBG2

— Kathleen Schmeler MD (@kmschmeler) March 26, 2018

Ovarian Cancer - Niraparib and Pembrolizumab

Late Breaking Abstract: Dr. Konstatinopoulos presents results of niraparib and pemrolizumab combo in heavily pretreated platinum resistant ovarian cancer #SGOmtg #gyncsm pic.twitter.com/zWhSRVAhx4

— Annie Ellis (@Stigetta) March 26, 2018

Ovarian Cancer - Olaparib and Durvalumab

Olaparib + durvalumab ORR of 72% in plt sens recurrent #ovariancancer gBRCA pos patients #SGOMtg pic.twitter.com/hio2vSVxmM

— Alpa Nick (@AlpaNick) March 26, 2018

Late Breaking Abstract session: Dr. Drew presents results of MEDIOLA basket trial of olaparib and durvalumab combo in relapsed BRCA+ platinum sensitive ovarian cancer #SGOmtg #gyncsm pic.twitter.com/lycZZlxYYR

— Annie Ellis (@Stigetta) March 26, 2018

 Ovarian Cancer- Metastasis and DDR2 experssion

M Greenwade presents work to understand stromal expression of DDR2 and control ovarian cancer metastasis #SGOmtg #gyncsm pic.twitter.com/wGE4w44Qaf

— Annie Ellis (@Stigetta) March 26, 2018

Palliative care

Palliative care: not just for end of life. New model includes life prolonging care from diagnosis. Very important for QoL throughout treatment and beyond! #SGOMtg #gyncsm pic.twitter.com/tyGDFxkACz

— Annie Ellis (@Stigetta) March 25, 2018

Survivorship / BMI and Risk

Endometrial cancer is one of the 3 obesity-driven cancers in women. Only 1% of #endometrial and #ovarian cancer patients are meeting the 2006 ACS guidelines for #cancersurvivors - Dr. Von Gruenigen #SGOMtg pic.twitter.com/EAX08fQOqN

— Ali Saiz (@aulyouneedisluv) March 26, 2018

Fantastic sunrise seminar on survivorship! Survivors need to be empowered with information after front line treatment. Reduce risk and screen for secondary cancers. #sgomtg #gyncsm pic.twitter.com/OLyOW0E4lL

— Annie Ellis (@Stigetta) March 26, 2018

Lay navigation

Lay navigation (non clinical) for pts w/ gyn cancers. Navigation triggered via distress scores/risk factors, then triage pt to resources. Study: how did this service impact cost? 1052 patients; 37% navigated. Navigated pts=57% ⬇ in total costs & ⬇ in hospitalization#SGOmtg

— Erica Bednar (@EMBOSU) March 26, 2018

Granulosa Cell tumors

Excellent presentation by @RTylerHillmanMD identifying KMT2D mutations in granulosa cell tumors #SGOMtg pic.twitter.com/EhcSeeq3ci

— Aaron Shafer (@aaronshafer99) March 26, 2018

@RTylerHillmanMD presents high quality sequencing used to identify KMT2D predicting recurrence in granulosa cell #ovariancancer @MDAndersonNews #SGOMtg pic.twitter.com/imZZcpSYuz

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Thanks Dr Dood, Erica Bednar, Annie Ellis, Ali Saiz, Alpa Nick, Rick Boulay, Erin Stevens and Kathleen Schmeler for sharing on Twitter during the meeting.

Dee
Every Day is a Blessing!

#SGOmtg Twitter Highlights - Research Highlights Sunday March 25, 2018

Sunday was another busy day of information sharing at the SGO Annual Meeting in New Orleans.
Here are the topics that caught my eye while following the #SGOmtg hashtag.

Ovarian Cancer Maintenance Rucaparib - NOVA Study

#NOVA retrospective data show low wt & low baseline platelets associated w/ increased risk of Gr.3/4 thrombocytopenia w/ maintenance #rucaparib for #ovariancancer. #SGOmtg #gyncsm pic.twitter.com/JqSwALqoKR

— Deanna Teoh, M.D. (@DeannaTeoh) March 25, 2018

Ovarian Cancer - Niraparib and Cost effectiveness

#Niraparib maintenance for #ovariancancer not #costeffective unless drug cost drastically reduced. Need to advocate for #DecreasedDrugCosts. #SGOmtg #gyncsm pic.twitter.com/qwbGelJYgG

— Deanna Teoh, M.D. (@DeannaTeoh) March 25, 2018

Ovarian Cancer - Parp inhibitor and BRCA status

Beautiful study demonstrating higher value of #PARPi for #BRCA mutant #ovariancancer compared to wild type. It is important to consider #PrecisionMedicine when making treatment decisions. #SGOMtg #gyncsm pic.twitter.com/tgyvD5i4Dk

— Shannon Westin (@ShannonWestin) March 25, 2018

Endometrial Cancer GOG 86 P Predictive biomarkers of endometrial cancer

Slides for today’s #SGOmtg GOG-86P translational science presentation are available at: https://t.co/dXapOLGXce

— Douglas Levine MD (@levinemd) March 25, 2018

Endometrial Cancer PORTEC3

PORTEC 3: in chemo/RT vs RT, role in stage III, balance with toxicity. So many exciting results coming out at #SGOMtg #gyncsm #endometrialcancer pic.twitter.com/n6a58Vy71t

— Jolyn Taylor (@TaylorJolyn) March 25, 2018

PORTEC3: ChemoRT vs RT alone: 5y FFS 76v69% (sig) 5yOS 82v77% (NS) #SGOMtg (H/T @stigetta)

— Don S Dizon (@drdonsdizon) March 25, 2018

Endometrial - GOG 249

Dr. Marcus Randall discussing GOG 249 results: pelvic RT vs chemo/brachy similar RFS and OS; more acute toxicity in chemo arm, similar late tox #SGOMtg #gyncsm #endometrialcancer pic.twitter.com/cT4zbjoUbc

— Jolyn Taylor (@TaylorJolyn) March 25, 2018

Cervical Cancer - chemo /radiation

Improved DFI but not OS in locally advanced cervical cancer itrated with chemo/RT as compared to neoadjuvant chemo followed by surgery. Recommend chemo/Rt #SGOMtg pic.twitter.com/3AhvmPAUcR

— Rick Boulay,MD (@journeycancer) March 25, 2018

Thank you to Rick Boulay,MD, Jolyn Taylor, Don S Dizon, Douglas Levine MD,  Shannon Westin and Deanna Teoh, M.D. for tweeting using the #SGOmtg hashtag so those of us following from a distance can learn.


Dee
Every Day is a Blessing!

SGO Meeting Highlights via Twitter ~ Day Two, March 13, 2017

More news from the The Society of Gynecologic Oncology (@SGO_org) Annual Meeting. I am at home and have been following Tweets from the meeting using the hashtag #SGOmtg.

Here are some tweets I found of interest today-  Monday, March 13th.

Endometrial Cancer:

More evidence that molecular/genetic makeup of endometrial CA in blacks explains poorer prognostic factors #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 13, 2017

Maxwell: High MS7 levels in primary tumor consistently associated with poor outcome in endometrial cancer. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Great study from @SArmbrusterMD: physical activity intervention associate w long term wt loss in EC pts at meet the prof #SGOMtg #endcancer

— Katie Kurnit (@katiekurnit) March 13, 2017

Burnout in Gynecologic  Oncologists

Dr. Fowler discussing strategies to address burnout. #SGOMtg #selfcare pic.twitter.com/AZ3SnRhUKW

— Shannon Armbruster (@SArmbrusterMD) March 13, 2017

Fowler Prez Addrs: Physician wellness=Better patient outcomes & Quality care. #SGOMtg We NEED you & we need you 2 take care of yourselves ❤

— Annie Ellis (@Stigetta) March 13, 2017

Patient Centered Assessment Tool - Great work done by my friend and fellow advocate Annie Ellis.

Poster 94: Priorities assessment tool (PAT) to support shared decision making, maximize appt time & increase patient satisfaction #SGOMtg pic.twitter.com/Kj7d1oa46M

— Annie Ellis (@Stigetta) March 13, 2017

IP Chemotherapy

OV21/PETROC trial. another trial that shows intraperitoneal chemotherapy for #ovariancancer patients is better. #SGOMtg #fightsmarter

— Rod Rocconi (@rodrocconi) March 13, 2017

Poster 148: no sig diff b/w bev and IP chemo in PFS or OS in pts with #BRCA positive #ovariancancer #SGOMtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Circulating DNA

ctDNA is the future of precision oncology for GYN patients and beyond! So many possibilities! #SGOMtg #endCancer

— Katie Kurnit (@katiekurnit) March 13, 2017

 Niraparib

Today we presented secondary endpoint data from our landmark NOVA trial at #SGOMtg. Read our press release for more: https://t.co/l9Hk9HULIa

— TESARO, Inc. (@TESAROBIO) March 13, 2017

Maintenance niraparib improved outcomes & not detrimental to QoL in heavily pretreated platinum sensitive gBRCAmut and non-gBRCAmut #SGOMtg pic.twitter.com/RGkJxDSkod

— Annie Ellis (@Stigetta) March 13, 2017

 Rucaparib

Latest updates for rucaparib for #ovariancancer in ARIEL2 trial , presented at @SGO_org #SGOMtg : https://t.co/ONXf5WtfMg pic.twitter.com/9TfNQoQ0wu

— ecancer (@ecancer) March 13, 2017

Genetic Testing

As we discuss genetic testing at #SGOMtg, important to remember the personal implications https://t.co/5KbrWG7NCw #ovarian cancer #gyncsm

— Dr. Robert Dood (@DrRobDood) March 13, 2017

 GPI -  Glucose-6-phosphate isomerase

Previs: High GPI levels in patients w ovca associated with worse prognosis. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Previs: GPI: glucose 6-phosphate isomerase. Previs finds that inhibition associated with more cell kill/less tumor burden. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Neoadjuvant Chemotherapy

R Arend: NACT for #ovariancancer leads to upregulation of #DNA damage repair pathway genes #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Arend: pt w/ #BRCA mutation had lowest DNA damage pathway score after NACT - further investigation needed #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Slides from a Sunday presentation on  PARP

Drs. Coleman, Herzog, @DrMatulonis, @ShannonWestin Downloadable Slides Now Available at https://t.co/FOiuvBPJzG from symposium at #SGOMtg pic.twitter.com/OChFoann3G

— BioAscend (@BioAscend) March 13, 2017

Thanks for all those tweeting from the meeting especially these folks

Follow the newest #socialmedia stars from @mdandersonnews 4 #gyncancer #SGOMtg updates @DrRobDood @katiekurnit @JDottinoMD @RTylerHillmanMD https://t.co/mVo1TZBt9D

— Shannon Westin (@ShannonWestin) March 13, 2017

Tweeting. #SGOMtg #gyncsm pic.twitter.com/dNrDqpZxut

— Robert Tyler Hillman (@RTylerHillmanMD) March 13, 2017

Looking forward to Tweets from tomorrow's meeting.

Dee Every Day is a Blessing!